Investigating Poor Cancer Outcomes in Hispanics

Investigating Poor Cancer Outcomes in Hispanics

Using national and local patient cohorts, Einstein-Montefiore researchers in the Division of Hemato-Oncology compared white and Hispanic patients diagnosed with acute myeloid leukemia (AML) and found that Hispanics present with AML at younger ages and have shorter survival than whites. In addition, Hispanic AML patients had an increased frequency of high-risk cancer mutations compared with whites. The findings, published online on October 26 in Blood Advances, suggest that the greater frequency of high-risk mutations among Hispanics may explain their worse AML outcomes compared with whites. The study’s senior author is Ioannis Mantzaris, M.D., M.S., assistant professor of medicine and attending physician at Montefiore Medical Center.